Sugi Predict

Sugi Predict / Compounds / SCHEMBL272122

SCHEMBL272122

SCHEMBL272122

OC[C@H]1O[C@@H](n2cnc3c(Cl)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 7/20 0.73
▸ STAT6 P42226 2/20 0.73
▸ DPP4 P27487 1/20 0.73
▸ MEN1 O00255 1/20 0.73
▸ SLC28A1 O00337 1/20 0.73
▸ MAP3K7 O43318 1/20 0.73
▸ SLC28A2 O43868 1/20 0.73
▸ GAPDH P04406 1/20 0.73
▸ ADORA3 P0DMS8 1/20 0.73
▸ MAPK1 P28482 1/20 0.73
▸ ADORA2A P29274 1/20 0.73
▸ ADORA2B P29275 1/20 0.73
▸ ADORA1 P30542 1/20 0.73
▸ PI4KA P42356 1/20 0.73
▸ KMT2A Q03164 1/20 0.73
▸ SMN1; SMN2 Q16637 1/20 0.73
▸ PI4K2B Q8TCG2 1/20 0.73
▸ DOT1L Q8TEK3 1/20 0.73
▸ PI4K2A Q9BTU6 1/20 0.73
▸ SLC28A3 Q9HAS3 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1858029 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL19443159 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL319667 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL278513 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL67126 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL10062644 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL272123 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL10340725 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL21139429 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL91050 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1813 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12460204-B2 Artificial nucleic acid molecules for improved protein or peptide expression CureVac SE (DE) 2025-11-04 — — US claimed
US-20250263678-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF RNA REJUVENATION TECHNOLOGIES, INC. (US) 2025-08-21 — — US claimed
WO-2025111452-A2 CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs PRIME MEDICINE, INC. (US) 2025-05-30 — — WO claimed
WO-2025111430-A1 CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL PRIME MEDICINE, INC. (US) 2025-05-30 — — WO claimed
US-20250136711-A1 SEMENOGELIN NEUTRALIZING ANTIBODY AND EPITOPE AND APPLICATION THEREOF SHANGHAI BIOTROY BIOTECHNIQUE CO., LTD (CN) 2025-05-01 — — US claimed
WO-2025043082-A2 COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS THE BROAD INSTITUTE, INC. (US) 2025-02-27 — — WO claimed
WO-2025038971-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
WO-2025038963-A1 OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
WO-2025038970-A1 MODIFIED OLIGONUCLEOTIDES CONTAINING MULTIPLE OLIGONUCLEOTIDES ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
WO-2025038960-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO claimed
EP-0755255-A1 TREATMENT OF TOXOPLASMOSIS UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) 1997-01-29 — — EP claimed
WO-1996018398-A1 TREATMENT OF TOXOPLASMOSIS THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) 1996-06-20 — — WO claimed
US-5474929-A Adenosine deaminase gene NATIONAL RESEARCH COUNCIL OF CANADA (CA) 1995-12-12 — — US claimed
WO-1994002497-A1 SULFO-DERIVATIVES OF ADENOSINE THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-02-03 — — WO claimed
EP-0305643-B1 N-6 thienyl substituted adenosine derivatives as cardiac vasodilators WHITBY RESEARCH INC (US) 1994-01-05 — — EP claimed
EP-0423776-A2 N-(6)-substituted adenosine compounds G.D. Searle & Co. (US) 1991-04-24 — — EP claimed
WO-1988003148-A2 HETEROAROMATIC DERIVATIVES OF ADENOSIDE WARNER-LAMBERT COMPANY (US) 1988-05-05 — — WO claimed
WO-1988003147-A1 SELECTED N6-SUBSTITUTED ADENOSINES HAVING SELECTIVE A2 BINDING ACTIVITY WARNER-LAMBERT COMPANY (US) 1988-05-05 — — WO claimed
EP-0222330-A2 N6-Substituted-5'-oxidized adenosine analogs WARNER-LAMBERT COMPANY (US) 1987-05-20 — — EP claimed
US-4088756-A TREATING PSORIASIS, DERMATITIS WITH ADRENERGIC AGENTS AND HYPOGLYCEMIC AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1978-05-09 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263678-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF RNA RNASE1, POLRMT, TERT SLC29A1 1862/4885STAT6 147/4885DPP4 2299/4885
US-12460204-B2 Artificial nucleic acid molecules for improved protein or peptide expression RNMT, NSUN3, RNGTT SLC29A1 2552/4885STAT6 41/4885DPP4 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.